GW5282
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for GW5282, covering 2026-02-11 to 2026-04-17. Get the full timeline:
Most recent: Clinical Trial Update: Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) [Phase 1, Phase 2]